Jiyun Jo

Business development

• Supported and motivated partners to deliver contractual commitment by providing differentiated digital channel and individualized communication platform
• Developed integrated KPI tracker aligned with the contracts to evaluate and manage partners' performance regularly
• Led regular training meetings to develop qualified commercial capability of FFs(Internal and External) to maximize business opportunities of Sandoz portfolio
• Analyzed new business opportunities to widen targeted TAs or molecules by analyzing secondary data and gathering key insights

Key stakeholders Engagement

• Delivered the value of pre/post-launched products through the respective product strategy & related initiatives (Train The Trainees programs, Small group symposiums, etc.)
• Built strong partnership with KNPA(Korean Neuropsychiatric Association) and KSAD(Korean Society for Affective Disorders) through discussion to develop disease awareness programs
• Led Asia regional commercial initiative(Sandoz Health Talk Asia) to strengthen company positioning in Asia region
• Collaborated with cross-functional teams to ensure operational effectiveness and efficiency

Strategic Planning for Business Excellence

• Enhanced performance/financial reports with Finance team to support business decision making and work efficiency
• Worked with the regional team to enhance a forecasting model for analyzing and predicting future results accurately and maximize the business opportunity
• Developed commercial operation plan of CNS /Oncology portfolio and ANE product aligned with local business needs

Maximizing business opportunity for sustainable growth

• Achieved $5.2M by successfully driving expanded reimbursement after re-supply in DME(Diabetic Macular Edema) and BRVO(Branch Retinal Vein Occlusion) indication and ranked 3rd out of 23 “Focus to accelerate” countries (Re-call period in Q4 2018 - Q1 2019)
• Developed successful network between KEEs(Key External Experts) in Korea and Asia sub-region by conducting academy program with Seoul National University hospital
• Maximized Share of Voice Pre/Post re-supply by media release and flawless execution, and fully amplified key advocate voice at congress of academia and symposiums
• Reprioritized HCP segmentation regarding to remained potential, and conducted monthly key account management review meeting to monitor KPI progress and root causes of each account
• Built strong partnership with KRS(The Korean Retina Society), KUS(Korean Uveitis Society) and KARD(Korean Association of Retina Degeneration) through discussion on local guideline development
• Created company brand messaging, collateral materials, customer events, promotional strategies and product commercialization

Integration of insight and analysis

• Leveraged integrated secondary and primary market data and brand performance to gain in-depth market intelligence, and find actionable opportunities
• Identified key implications of the market, HCPs and patients by analyzing both internal data (primary data) and external data (secondary data e.g., IQVIA audit, Normal/Direct DDD, HIRA NPS, Syndicated data, etc.), and reflected the insights in the brand strategy and forecast
• Developed patient models for each indication by integrating various sources such as secondary data, papers, guidelines and KEE feedback to forecast the value, volume, and M/S% of the product over the next 10 years
• Enhanced performance/financial reports (e.g., Dashboard) with Finance/BE team

Product Launch Readiness

• Product Launch Readiness Led Ozurdex re-launch project in collaborative with cross-functional team (Medical Affairs, Regulatory Affairs, Commercial Quality, Supply Chain, Business Excellence, Medical and Sales team)
• Enhanced the PSP(Patient Support Program) scheme to expand the coverage for economically challenged patients in DME and BRVO indication
• Supported the global commercial operations (Sales Forecasting & Analysis) team to develop the Abicipar revenue/patient number forecasting model

Strong performance track record and marketing excellence of Respiratory portfolio

• Achieved $10.0M driving with growth >10% in 2017-2019 by reaching No.1 Share of Voice product in ICS/LABA market in clinic sector
• Supported and reported operation & strategic plan to BU head, and tracked financial accomplishments and forecasts
• Led marketing initiatives through a strong collaboration with KATRD(The Korean Academy of Tuberculosis and Respiratory Diseases) and KAAACI(The Korean Academy of Asthma, Allergy and Clinical Immunology) as a project owner
• Screened non-target customers by leveraging Multi-Channel Marketing tools to widen coverage rate, and linked key marketing initiatives
• Developed innovative segmentation & targeting model with call resource optimization to expand clinic coverage without additional sales force investment

Business excellence and New launch product readiness

• Led regular operation plan meetings to update forecast, followed up various strategic marketing programs and supported business decisions
• Developed a brand plan and reported commercial parts (Sales, Marketing, etc.) to CEO & executives
• Led value added secondary data analyses (IMS, DDD, UBIST and HIRA, etc.) and gave insights into business performance and strategy development
• Developed business cases for new products (Fasenra, Bevespi and PT010) to prepare the launch strategy

Asthma and COPD ‘patients journey’ development

• Implemented “Korean asthma and COPD patients' journey” deep dive market research which was the first project in Asia region to find out triggering points and leakage points to apply the key findings into 2019 brand strategy & operation plan with feedback from KEE

Strong collaboration with sales team and other cross-functional team

• Worked on ‘Healthy lung' project to shape the environment with internal(medical, market access team)/external(academic societies) key stakeholders
• Developed business case to check impact of reimbursement expansion of Daxas with market access team

Outstanding sales performance

• Achieved phenomenal sales results and ranked No.1 in sales nationwide all throughout 2017 “President” award and “Top performer” award 3 times for 3 years
• Achieved more than 80% market share on Symbicort from "Beautiful breath clinic" No.1 respiratory clinic in Korea
• Received recognition for excellent driving business and ability to develop solid, long-term relationship with diverse clients
• Developed in-depth knowledge of market, demographic, and information on targeted hospitals and utilized the knowledge to identify new opportunities and strengthen relationships with customers